{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:46:53Z","timestamp":1770745613708,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Damoctocog alfa pegol (BAY 94\u20109027, Jivi<jats:sup>\u00ae<\/jats:sup>) is an approved extended half\u2010life factor VIII (FVIII) for treatment of previously treated patients with haemophilia A aged \u226512 years. We report the final results of an interventional, post\u2010marketing study of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this open\u2010label, interventional, post\u2010marketing, phase 4 trial (NCT04085458), previously FVIII\u2010treated patients with severe haemophilia A aged \u226518 years received damoctocog alfa pegol for \u2265100 exposure days (EDs). Patients initially received 45\u00a0IU\/kg every 5 days (recommended) or 40\u00a0IU\/kg twice\u2010weekly. At Visit\u00a03, patients\u2019 doses could be increased, or treatment frequency adapted. The primary endpoint was FVIII inhibitor development (titre \u2265.6\u00a0Bethesda units). Secondary endpoints included anti\u2010polyethylene glycol (PEG) antibody development, treatment\u2010emergent adverse events (AEs) and annualized bleeding rate (ABR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 36 patients were enrolled; 32 patients received treatment, of whom, 27 completed the study. No patients developed FVIII inhibitors; three tested transiently positive for low\u2010titre anti\u2010PEG antibodies without clinical relevance. Three patients reported study\u2010drug\u2010related AEs of mild or moderate intensity. Two patients discontinued the study due to AEs. No deaths occurred. Most patients (70%) were treated with E5D\/E7D regimens. The median (Q1;Q3) total ABR (<jats:italic>N<\/jats:italic>\u00a0=\u00a030) was 3.0 (.0;9.0) pre\u2010study and 1.8\u00a0(.7;5.9) during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Damoctocog alfa pegol individualized prophylaxis regimens were well\u2010tolerated with no immunogenicity concerns. ABRs improved following the switch from pre\u2010study prophylaxis to damoctocog alfa pegol prophylaxis. These results support the favourable safety and efficacy profile of damoctocog alfa pegol prophylaxis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14930","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T05:49:16Z","timestamp":1705470556000},"page":"388-394","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post\u2010marketing study"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-2905","authenticated-orcid":false,"given":"P\u00e5l Andr\u00e9","family":"Holme","sequence":"first","affiliation":[{"name":"Department of Haematology Oslo University Hospital and Institute of Clinical Medicine University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[{"name":"The Haemophilia Centre Aarhus University Hospital  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Tueckmantel","sequence":"additional","affiliation":[{"name":"Bayer AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Maas Enriquez","sequence":"additional","affiliation":[{"name":"Bayer AG  Wuppertal Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3296-4288","authenticated-orcid":false,"given":"Mar\u00eda Teresa","family":"Alvarez Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimondo","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"Agostino Gemelli University Hospital Foundation IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13853"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04214.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1002465"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14297"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02838.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100828"},{"key":"e_1_2_11_10_1","unstructured":"EMA.Guideline on the clinical investigation of recombinant and human plasma\u2010derived factor VIII products.2017. EMA\/CHMP\/BPWP\/144533\/2009 rev. 2."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000658"},{"issue":"1","key":"e_1_2_11_13_1","first-page":"82","article-title":"EAHAD P0111","volume":"29","author":"Holme PA","year":"2023","journal-title":"Haemophilia"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T02:06:23Z","timestamp":1714442783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/hae.14930"],"URL":"https:\/\/doi.org\/10.1111\/hae.14930","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"2023-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}